A liquid chromatography-tandem mass spectrometry method for the determination of 5-fluorouracil degradation rate by intact peripheral blood mononuclear cells

Therapeutic Drug Monitoring

Volumn 31, Issue 4, 2009, Pages 482-488

  Lostia, Alfonso M ^a   Lionetto, Luana ^a   Ialongo, Cristiano ^a   Gentile, Giovanna ^a   Viterbo, Antonella ^a   Malaguti, Paola ^a   Paris, Ida ^a   Marchetti, Luca ^a   Marchetti, Paolo ^a   Blasi, Antonio De ^a   Simmaco, Maurizio ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

5 fluorouracil; Dihydropyrimidine dehydrogenase; LC MS MS; Peripheral blood mononuclear cells, therapeutic drug monitoring; Personalized medicine

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; COLON ADENOCARCINOMA; CONTINUOUS INFUSION; CONTROLLED STUDY; DEHYDRATION; DRUG DEGRADATION; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HYPONATREMIA; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PYROSEQUENCING; RECTUM CARCINOMA; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM; TANDEM MASS SPECTROMETRY;

AGED; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; FLUOROURACIL; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; REFRACTORY PERIOD, PSYCHOLOGICAL; TANDEM MASS SPECTROMETRY;

EID: 68449102453     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181ae4516     Document Type: Article

References (26)

1. Hiroyuki B, Kenichi T, Toru K, et al. Dihydropyrimidine dehydrogenase and thymidylate synthase activities in hepatocellular carcinomas and in diseased livers. Cancer Chemother Pharmacol. 2003;52:469-476.
2. Etsuko S, Hideki N, Takashi K, et al. Orate phosphoribosyltransferase expression level in tumors is a potential determinant of the efficacy of 5-fluorouracil. Biochem Biophys Res Commun. 2007;363:216-222.
3. Das P, Lin EH, Bhatia S, et al. Preoperative chemoradiotherapy with capecitabine versus protracted infusion 5-fluorouracil for rectal cancer: a matched-pair analysis. Int J Radiat Oncol Biol Phys. 2006;66:1378-1383.
4. Porschen R, Arkenau HT, Kubicka S, et al. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. J Clin Oncol. 2007;25:4217-4223.
5. Miyazaki K, Shibahara T, Sato D, et al. Influence of chemotherapeutic agents and cytokines on the expression of 5-fluorouracil-associated enzymes in human colon cancer cell lines. J Gastroenterol. 2006;41:140-150.
6. Jane LY, Howard L. Should DPD analysis be required prior to prescribing fluoropyrimidines? Eur J Cancer. 2007;43:1011-1016.
7. Deporte-Fety R, Picot M, Amiand M, et al. High-performance liquid chromatographic assay with ultraviolet detection for quantification of dihydrofluorouracil in human lymphocytes: application to measurement of dihydropyrimidine dehydrogenase activity. J Chromatogr B Biomed Sci Appl. 2001;762:203-209.
8. Van Kuilenburg ABP, Klumpen HJ, Westermann AM, et al. Increased dihydropyrimidine dehydrogenase activity associated with mild toxicity in patients treated with 5-fluorouracil and leucovorin. Eur J Cancer. 2007;43:459-465.
9. Guimbaud R, Guichard S, Dusseau C, et al. Dihydropyrimidine dehydrogenase activity in normal, inflammatory and tumour tissues of colon and liver in humans. Cancer Chemother Pharmacol. 2000;45:477-482.
10. Van Kuilenburg ABP, Van Lenthe H, Zoetekouw L, et al. HPLC-electrospray tandem mass spectrometry for rapid determination of dihydropyrimidine dehydrogenase activity. Clin Chem. 2007;53:528-530.
11. Milano G, Etienne MC, Pierrefite V, et al. Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity. Br J Cancer. 1999;79:627-630.
12. Van Kuilenburg ABP, Van Lenthe H, Tromp A, et al. Pitfalls in the diagnosis with a partial dihydropyrimidine dehydrogenase deficiency. Clin Chem. 2000;46:9-17.
13. Johnson MR, Yan J, Shao L, et al. Semi-automated radioassay for determination of dihydropyrimidine dehydrogenase (DPD) activity, screening cancer patients for DPD deficiency, a condition associated with 5-fluorouracil toxicity. J Chromatogr B Biomed Sci Appl. 1997;696:183-191.
14. Johnson MR, Wang K, Smith JB, et al. Quantification of dihydropyrimidine dehydrogenase expression by real-time reverse transcription polymerase chain reaction. Anal Biochem. 2000;278:175-184.
15. Seck K, Riemer S, Kates R, et al. Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in a cohort of Caucasian individuals. Clin Cancer Res. 2005;11:5886-5892.
16. Zhou ZW, Wang GQ, Wan S, et al. The dihydrouracil/uracil ratios in plasma and toxicities of 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer patients. Chemotherapy. 2007;53:127-131.
17. Milano G, Chamorey AL. Clinical pharmacokinetics of 5-fluorouracil with consideration of chronopharmacokinetics. Chronobiol Int. 2002;19:177-189.
18. Van Kuilenburg AB, Haasjes J, Richel DJ, et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res. 2000;6:4705-4712.
19. Di Paolo A, Danesi R, Falcone A. Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients. Ann Oncol. 2001;12:1301-1306.
20. Bocci G, Barbara C, Vannozzi F, et al. A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity. Clin Pharmacol Ther. 2006;80:384-395.
21. Alsarra IA, Alarifi MN. Validated liquid chromatographic determination of 5-fluorouracil in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2004;804:435-439.
22. Guidance for Industry, Bioanalytical Method Validation. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research; 2001. Available at: http://www.fda.gov/CDER/ GUIDANCE/4252fnl.pdf. Accessed June 20, 2009.
23. Shah VP, Midha KK, Findlay JW, et al. Bioanalytical method validation - a revisit with a decade of progress. Pharm Res. 2000;17:1551-1557.
24. Porter DJ, Spector T. Dihydropyrimidine dehydrogenase. Kinetic mechanism for reduction of uracil by NADPH. J Biol Chem. 1993;268:19321-19327.
25. Tuchman M, Ramnaraine ML, O'Dea RF. Effects of uridine and thymidine on the degradation of 5-fluorouracil, uracil, and thymine by rat liver dihydropyrimidine dehydrogenase. Cancer Res. 1985;45:5553-5556.
26. Annesley TM. Ion suppression in mass spectrometry. Clin Chem. 2003;49:1041-1044.